Back to top
more

Akero Therapeutics (AKRO)

(Real Time Quote from BATS)

$27.64 USD

27.64
442,387

-2.12 (-7.12%)

Updated Nov 15, 2024 01:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody

by Zacks Equity Research

BioNTech (BNTX) announces positive initial data evaluating BNT316/ONC-392 to treat metastatic non-small cell lung cancer.

Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros

by Zacks Equity Research

Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.

Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study

by Zacks Equity Research

Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.

Bayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies

by Zacks Equity Research

Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.

Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design

by Zacks Equity Research

Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.

AstraZeneca (AZN) Discontinues Brazikumab Development

by Zacks Equity Research

AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.

PepGen (PEPG) Down on Clinical Hold for DM1 Candidate

by Zacks Equity Research

PepGen (PEPG) shares fall after FDA places clinical hold on a study evaluating potential treatment for myotonic dystrophy.

J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH

by Zacks Equity Research

J&J (JNJ) submits a new drug application for a single tablet combination therapy of macitentan and tadalafil for the long-term treatment of pulmonary arterial hypertension.

Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval

by Zacks Equity Research

Lexicon's (LXRX) shares rise as it receives FDA approval for Inpefa, a once-daily oral tablet to treat a broad population of heart failure patients.

AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal

by Zacks Equity Research

AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.

Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails

by Zacks Equity Research

Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral sclerosis fails to meet primary and key secondary endpoints.

Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use

by Zacks Equity Research

Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.

INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up

by Zacks Equity Research

INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug designation from the European Commission.

How Much Upside is Left in Akero Therapeutics, Inc. (AKRO)? Wall Street Analysts Think 29.22%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 29.2% in Akero Therapeutics, Inc. (AKRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus

by Zacks Equity Research

Immunovant (IMVT) reports narrower-than-expected results in fourth-quarter fiscal 2023. Pipeline development is on track. Stock surges 12% on Monday.

Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study

by Zacks Equity Research

A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.

Here's Why Momentum in Akero Therapeutics, Inc. (AKRO) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Akero Therapeutics, Inc. (AKRO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.

Why Earnings Season Could Be Great for Akero Therapeutics (AKRO)

by Zacks Equity Research

Akero Therapeutics (AKRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Novo Nordisk (NVO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have increased sales in the first quarter of 2023, amid severe competition and pricing pressure in the United States.

Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?

by Zacks Equity Research

Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.

Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.

Can Akero Therapeutics, Inc. (AKRO) Climb 42.57% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 42.6% upside potential for Akero Therapeutics, Inc. (AKRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study

by Zacks Equity Research

Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.